Khella

Related Terms

Ammi, Ammi daucoides, Ammi visnaga, Bischofskrautfruchte, bishop's weed, bishop's weed fruit, daucus visagna, false Queen Anne's lace, fruits de khella, germakellin, honeyplant, khellin, picktooth, Spanish toothpick, toothpick plant, visnaga, visnagae, Visnagafruchte, visnagin.

Background

Khella (Ammi visnaga) was originally cultivated by the ancient Egyptians who used it to treat many ailments, including urinary tract diseases. It was also used in the Middle Ages as a diuretic.
The whole fruit has traditionally been used to treat respiratory system diseases such as asthma, bronchitis, emphysema and whooping cough, as well as cardiovascular disorders, premenstrual syndrome (PMS), liver and gall bladder disorders and to stimulate diuresis (increase in urine production). Its purported effect is related to its antispasmodic action on smaller bronchial muscles, coronary arteries and urinary tract tubules. Ammi visnaga may vasodilate the coronary arteries, which increases the blood supply to the myocaridium, and as a result, can be used to treat mild forms of angina (chest pain). It is also used to treat problems associated with spasms and constriction of the gallbladder and bile duct and facilitates the discharge of kidney stones and gallstones.
The clinical and therapeutic effectiveness of khellin, a constituent of khella, with respect to coronary, respiratory and urologic indications, has been demonstrated in experiments. Current khella indications include mild angina (chest pain) complaints, postoperative treatment of urinary calculus (kidney stones) and supportive treatment of mild forms of obstructive pulmonary diseases.
Few clinical trials have investigated khella (the whole herb vs. its constituent khellin). However, based on traditional use, more studies of khella for the treatment of psoriasis (chronic skin disease) or lipid panel may be warranted.

Evidence Table

These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *
These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. GRADE *


Preliminary evidence suggests that khellin, taken by mouth, may be an effective therapy for psoriasis. However, additional study is needed to confirm these results.

 C


Preliminary evidence suggests that khellin, taken by mouth, may be an effective therapy for psoriasis. However, additional study is needed to confirm these results.

 C


Several studies have investigated the use of khellin for the treatment of vitiligo. However, the evidence of the efficacy of khellin is conflicting. Further research is warranted in order to draw a firm conclusion.

 C


Several studies have investigated the use of khellin for the treatment of vitiligo. However, the evidence of the efficacy of khellin is conflicting. Further research is warranted in order to draw a firm conclusion.

 C
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)
* Key to grades

A: Strong scientific evidence for this use
B: Good scientific evidence for this use
C: Unclear scientific evidence for this use
D: Fair scientific evidence for this use (it may not work)
F: Strong scientific evidence against this use (it likley does not work)

Tradition / Theory

The below uses are based on tradition, scientific theories, or limited research. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider. There may be other proposed uses that are not listed below.

Dosing

Adults (over 18 years old)
There is no proven safe or effective dose for khella. For vitiligo (loss of skin pigment), weekly applications of a 2% solution of khellin in acetone and propylene glycol (90 and 10%, respectively) with exposure to 90 minutes of sunlight for a period of four months has been studied. Traditionally, 30-60 drops of khella have been taken three to five times daily. An infusion of 1 teaspoon of crushed seeds per cup of water, infused for 25 minutes; or 1:3 dry liquid extract: 20-60 drops 1-4 times daily in a little water has also been used.

Safety

The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.

Interactions

Interactions with Drugs
Khella may decrease the toxicity of the cardiac glycoside digoxin due to the coronary vasodilator and antiarrhythmic effects of khella.

Attribution

This information is based on a systematic review of scientific literature edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).

Bibliography

Abdel-Fattah A, Aboul-Enein MN, Wassel G, et al. Preliminary report on the therapeutic effect of khellin in psoriasis. Dermatologica 1983;167(2):109-110.
Abdel-Fattah A, Aboul-Enein MN, Wassel GM, et al. An approach to the treatment of vitiligo by khellin. Dermatologica 1982;165(2):136-140.
Blumenthal M, Goldberg A, Brinckmann J, et al. Herbal Medicine, Expanded Commission E Monographs. Boston, MA: Integrative Medicine Communications, 1998.
Brinker F. Herb Contraindications and Drug Interactions. 2nd ed. ed. Eclectic Medical Publications: Sandy, OR, 1998.
Chrysanthis K. [Infusion of khella seeds in the treatment of bronchial asthma.]. Cyprus Med J 1950;3(4):333-335.
de Leeuw J, van der BN, Maierhofer G, et al. A case study to evaluate the treatment of vitiligo with khellin encapsulated in L-phenylalanin stabilized phosphatidylcholine liposomes in combination with ultraviolet light therapy. Eur J Dermatol 2003;13(5):474-477.
Franchi GG, Bovalini L, Martelli P, et al. High performance liquid chromatography analysis of the furanochromones khellin and visnagin in various organs of Ammi visnaga (L.) Lam. at different developmental stages. J Ethnopharmacol 1985;14(2-3):203-212.
Hudson J, Towers GHN. Phytomedicines as antivirals. Drugs Fut 1999;24(3):295-320.
Martelli P, Bovalini L, Ferri S, et al. Rapid separation and quantitative determination of khellin and visnagin in Ammi visnaga (L.) Lam. fruits by high-performance liquid chromatography. J Chromatogr 1984;301(1):297-302.
Morliere P, Honigsmann H, Averbeck D, et al. Phototherapeutic, photobiologic, and photosensitizing properties of khellin. J Invest Dermatol 1988;90(5):720-724.
Orecchia G, Perfetti L. Photochemotherapy with topical khellin and sunlight in vitiligo. Dermatology 1992;184(2):120-123.
Stevens TJ, Jones BW, Vidmar TJ, et al. Hypocholesterolemic effect of khellin and khelloside in female cynomolgus monkeys. Arzneimittelforschung 1985;35(8):1257-1260.
Stevens TJ, Phillips WA, Day CE. Comparative effects of khellin and timefurone on serum parameters in normal male cynomolgus monkeys. J Med Primatol 1985;14(5):255-262.
Uhlenbroock K, Mulli K. [Khellin, a contribution to pharmacology of the constituents of Ammi visnaga. 3.]. Arzneimittelforschung 1953;3(5):219-223.
Valkova S, Trashlieva M, Christova P. Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA. Clin Exp Dermatol 2004;29(2):180-184.